Salubris Pharmaceuticals Advances Two Class 1 New Drugs Targeting the RMB 120 Billion Cardiovascular Market

Recently,SalubrisTwo Class 1 new chemical drugs have achieved new progress: SAL0167 tablets have received initial approval for clinical trials, intended for the treatment of hyperlipidemia; SAL0137 tablets have initiated a Phase II clinical trial, intended for elevated lipoprotein(a). Data from Menet shows that in 2025, sales of cardiovascular and cerebrovascular system chemical drugs across China’s three major terminals and six major markets exceeded RMB 120 billion.

SAL0167 Tablets are a Class 1 innovative cyclic peptide drug, independently developed by Salubris with independent intellectual property rights, intended for the treatment of hyperlipidemia. Data from Menet shows that the new drug was first accepted by the CDE in April 2026 and received implicit approval for clinical trials for the first time in July of the same year (Acceptance Number: CXHL2600517).

SAL0137, a Class 1 novel oral small-molecule Lp(a) inhibitor, is at the forefront of global development among oral drugs targeting the same mechanism. According to the China Clinical Trial Database on Menet, Salubris has recently initiated a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of oral SAL0137 tablets in adult patients with elevated cardiovascular event risk and elevated lipoprotein(a) (Registration No.: CTR20262559). The target enrollment in China is 120 participants.

In China’s three major terminals and six major markets (see the end of this article for the statistical scope), sales of chemical drugs for cardiovascular and cerebrovascular diseases exceeded RMB 120 billion in 2025, representing a slight year-on-year decline. In terms of channel distribution, public hospitals accounted for more than half of the market, with a share exceeding 56%. By therapeutic subcategory, antihypertensive drugs led with a 55.31% market share, followed by lipid-regulating agents and cardiac disease treatments, which held shares of over 20% and 13%, respectively.

In 2025, among the top pharmaceutical groups in the systematic chemical drug market for cardiovascular and cerebrovascular diseases across China’s three major terminals and six key markets, Viatris, Novartis, AstraZeneca, Bayer, and China Resources Pharmaceutical ranked as the top five, with a combined market share of approximately 30%; Salubris ranked 11th, achieving a sales growth rate of 31.89% and marketing seven products.

In recent years, Salubris has actively pursued innovative transformation and continuously increased its R&D investment. The company’s R&D expenditure in 2025 amounted to RMB 1.266 billion, representing a year-on-year increase of 24.51% and accounting for 29.1% of its revenue. In the first quarter of 2026, R&D expenses reached approximately RMB 131 million, a year-on-year increase of 21.44%.

Among these, chronic disease medications represent one of Salubris’ key strategic focus areas. Since the beginning of this year, six new drug candidates have reached the Investigational New Drug (IND) application stage or beyond, primarily spanning therapeutic subcategories including antidiabetic agents, antihypertensive agents, lipid-regulating agents, treatments for biliary/hepatic diseases, and calcium homeostasis regulators.

The six new drugs comprise four chemical drugs and two biologics, predominantly Class 1 new drugs. Among them, the Class 3.4 biologic new drug, Recombinant Teriparatide for Injection, has been approved for marketing for the treatment of postmenopausal osteoporosis, marking the first weekly teriparatide formulation in China. The Class 1 chemical new drug SAL0145 Injection and the Class 1 biologic new drug SAL0150 Tablets are intended for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and diabetes, respectively, and are currently undergoing Phase I clinical trials.